In this year's report we are pleased to present figures and highlights for 2016 together with selected project examples.
Based on research at our partner institutes, two products received market approval and three clinical trials started in 2016. In addition, Cardior Pharmaceuticals GmbH was founded and six portfolio companies received new or extended financing, including EUR 9 million Series A financing for HepaRegenix last December.
The project pipeline is well filled: last year we intensively supported six further start-ups and several technology developments, examined around 100 new invention disclosures and concluded over 100 agreements, 39 of which revenue-generating.
Our partners’ revenues in 2016 from licence, option and material transfer agreements negotiated by us totalled over EUR 11 million. Furthermore, Ascenion distributed EUR 1 million to the LifeScience Foundation, most of which was made available as funding for research projects at the Foundation’s endowing institutes.
We are particularly delighted that two further partner institutes chose to become endowing institutes of the LifeScience Foundation last year: Charité – Universitätsmedizin Berlin and the Research Center Borstel (FZB), an institute of the Leibniz Association.
Our thanks go to all endowing and partner institutes, whose research activities and trust in our team form the basis for successful technology transfer.